SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

del-zota

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating4/10
Trial phase
Filed/PDUFA (BLA under Priority Review, Accelerated Approval pathway)
Time to market
PDUFA decision expected around March 2027 (Priority Review, 6-month clock from September 8, 2026 BLA acceptance). If approved, commercial launch would follow weeks to months after.
Why 4/10
The next hard catalyst is the FDA PDUFA decision on del-zota's BLA under Priority Review (Accelerated Approval pathway). The exact date has not been publicly disclosed by Novartis, but with Priority Review's 6-month clock from the September 8, 2026 acceptance, a decision is expected around March 2027. For a company the size of Novartis (~$200B+ market cap), this single drug is a small part of a massive diversified pipeline, so the impact score is capped at 4.
Actionable Insight NEUTRAL

The next catalyst is the FDA's decision on del-zota's BLA under Priority Review (Accelerated Approval pathway). Novartis has not disclosed the exact PDUFA date, but with Priority Review's 6-month clock from the September 8, 2026 acceptance, a decision is expected around March 2027. An approval would mark the first approved exon 44 skipping therapy for DMD; a Complete Response Letter would pressure the Avidity acquisition thesis and the broader neuromuscular pipeline.

Price Chart

Loading chart...

Executive Summary

Del-zota (delpacibart zotadirsen) is a first-in-class antibody-oligonucleotide conjugate being developed by Novartis (NVS) for Duchenne muscular dystrophy patients whose mutations are amenable to exon 44 skipping (DMD44), a subset with no approved therapy. Novartis acquired the asset through its ~$12B purchase of Avidity Biosciences in October 2025. The FDA accepted the BLA for Priority Review under the Accelerated Approval pathway on September 8, 2026, supported by Phase 1/2 EXPLORE44 data showing up to 67% exon skipping and increased dystrophin expression. The exact PDUFA date has not been disclosed but is estimated around March 2027. A global Phase 3 confirmatory trial (SAFARI44) is recruiting. For Novartis, a ~$200B+ diversified pharma giant, del-zota is a small pipeline component, the stock impact of any single FDA decision is limited, though the drug is strategically important to the company's neuromuscular franchise built via the Avidity acquisition.

How It Works

Del-zota is a first-in-class antibody-oligonucleotide conjugate (AOC). Think of it as a guided delivery system: an antibody that targets a receptor found on muscle cells (transferrin receptor 1) is attached to a short piece of synthetic DNA-like material (a PMO). The antibody acts like a homing beacon, carrying the PMO payload specifically to skeletal and heart muscle cells. Once inside, the PMO performs 'exon 44 skipping', it effectively tells the cell's protein-making machinery to skip over a faulty section of the dystrophin gene, allowing the cell to produce a shortened but still functional version of the dystrophin protein that Duchenne patients lack.

Trial Status

Phase 1/2 EXPLORE44 trial (NCT05670730) completed with positive results published in The Lancet Neurology. Open-label extension (EXPLORE44-OLE, NCT06244082) ongoing. Global Phase 3 confirmatory trial SAFARI44 (NCT07587242) is currently recruiting. BLA was accepted by FDA for Priority Review under Accelerated Approval pathway on September 8, 2026.

The Two-Sided Case

▲ Bull Case4
There are no approved exon 44 skipping therapies for DMD, del-zota would be first-to-market for this specific mutation subset, addressing a clear unmet need.
Phase 1/2 EXPLORE44 data showed statistically significant exon 44 skipping (up to 67%), increased dystrophin expression, and decreased CK biomarkers, with an acceptable safety profile, published in The Lancet Neurology.
The FDA granted Breakthrough Therapy, Priority Review, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, signaling strong regulatory alignment.
The antibody-oligonucleotide conjugate (AOC) technology is designed to deliver PMO payloads directly to skeletal and cardiac muscle, potentially overcoming the delivery limitations of earlier exon-skipping therapies.
▼ Bear Case4
The Phase 3 confirmatory trial (SAFARI44) is still recruiting, the BLA rests on Phase 1/2 data (26 patients), and the FDA's Accelerated Approval pathway requires a confirmatory study; if the confirmatory trial fails or is delayed, approval could be withdrawn or limited.
Novartis's other Avidity-acquired asset, del-desiran, failed its Phase 3 HARBOR study in DM1 on September 8, 2026, the same day del-zota's BLA acceptance was announced, raising questions about the broader AOC platform's clinical validity.
For a company the size of Novartis (~$200B+ market cap), del-zota is a small pipeline component; even a full approval would have limited impact on the stock.
Sarepta's exon-skipping drugs for other exons (45, 53) have faced confirmatory trial challenges, setting a precedent that the FDA may demand a high bar for accelerated approval conversion.

Upcoming Catalysts

  • FDA PDUFA decision on del-zota BLA, estimated around March 2027 (date not publicly disclosed by Novartis)
  • Phase 3 SAFARI44 trial enrollment and interim data readouts
  • Potential FDA Advisory Committee meeting if scheduled

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 9

Hover a chip for the title
1 parentprojectmd.org2 jettfoundation.org3 trialfriend.com4 novartis.com5 practicalneurology.com6 clinicaltrials.gov7 fiercebiotech.com8 aviditybiosciences.com9 novartis.com